The independent medical news service

Antibiotic use is associated with poor survival outcomes in people receiving tyrosine kinase inhibitors for advanced non-small-cell lung cancer or melanoma, findings indicate.

The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.

Age alone should not preclude the use of immune checkpoint inhibitors in people with cancer aged 80 years or more, say researchers who found promising efficacy and tolerability of single-agent therapy in this patient population.

A large single-center study has found an association between immune checkpoint inhibitor use and an increased incidence of venous thromboembolism in people with cancer.

A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.

Chinese researchers have used a combination of long noncoding RNA signatures and cytotoxic T-lymphocyte tumor infiltration to identify four distinct immune classes that may predict response to cancer immunotherapy.